FR3062303B1 - Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide - Google Patents

Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide Download PDF

Info

Publication number
FR3062303B1
FR3062303B1 FR1750853A FR1750853A FR3062303B1 FR 3062303 B1 FR3062303 B1 FR 3062303B1 FR 1750853 A FR1750853 A FR 1750853A FR 1750853 A FR1750853 A FR 1750853A FR 3062303 B1 FR3062303 B1 FR 3062303B1
Authority
FR
France
Prior art keywords
diol
cannabinoid compound
liquid vaporizable
vaporizable formulation
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1750853A
Other languages
English (en)
Other versions
FR3062303A1 (fr
Inventor
Antoine Piccirilli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Ceres Fr
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR1750853A priority Critical patent/FR3062303B1/fr
Publication of FR3062303A1 publication Critical patent/FR3062303A1/fr
Application granted granted Critical
Publication of FR3062303B1 publication Critical patent/FR3062303B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)

Abstract

[0001] Formulation liquide vaporisable comprenant au moins un composé cannabinoïde et au moins un diol choisi parmi les diols de Formule (I) : dans laquelle : R1 et R2 sont identiques ou différents, et sont choisis dans le groupe constitué par un atome d'hydrogène (-H) ou radical alkyle comprenant de 1 à 2 atomes de carbone ; m+n=1 ou m+n=2 ; n=0 ou n=1 ou n=2 ; - m=0 ou m=1 ; le diol étant sous forme de mélange d'isomères et/ou d'isomère isolé lorsqu'il comprend un ou plusieurs atomes de carbone asymétrique.
FR1750853A 2017-02-01 2017-02-01 Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide Active FR3062303B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1750853A FR3062303B1 (fr) 2017-02-01 2017-02-01 Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1750853A FR3062303B1 (fr) 2017-02-01 2017-02-01 Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide
FR1750853 2017-02-01

Publications (2)

Publication Number Publication Date
FR3062303A1 FR3062303A1 (fr) 2018-08-03
FR3062303B1 true FR3062303B1 (fr) 2019-11-29

Family

ID=59974492

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1750853A Active FR3062303B1 (fr) 2017-02-01 2017-02-01 Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide

Country Status (1)

Country Link
FR (1) FR3062303B1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2019152736A1 (fr) 2018-01-31 2019-08-08 Canopy Holdings, LLC Poudre de chanvre
WO2020077153A1 (fr) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthèse du cannabigérol
CA3118893A1 (fr) * 2018-11-06 2020-05-14 Columbia Care Llc Extrait de cannabinoide enrichi en terpene stabilise et ses procedes d'utilisation
FR3113563A1 (fr) * 2020-09-03 2022-03-04 Cids France Utilisation des phytocannabinoïdes végétaux extraits par méthode de distillation pour la fabrication de e-liquides
US20220280447A1 (en) * 2021-03-05 2022-09-08 Health Via Modern Nutrition Inc. Compositions and methods for improving brain function
US12059398B2 (en) 2022-08-26 2024-08-13 Health Via Modern Nutrition Inc. Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2207528B1 (fr) * 2007-10-05 2013-10-09 STI Pharmaceuticals Ltd. Composition pharmaceutique

Also Published As

Publication number Publication date
FR3062303A1 (fr) 2018-08-03

Similar Documents

Publication Publication Date Title
FR3062303B1 (fr) Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
BRPI0607062A2 (pt) composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
DE60118590D1 (de) Medizinische zusammensetzungen als begleittherapie gegen krebs
BRPI0502578A (pt) composições contendo agentes antiacne e uso das mesmas
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
WO2020113213A3 (fr) Dérivés de pantéthéine cyclique et utilisations de ceux-ci
RU2487124C2 (ru) Новое амидное производное и его использование в качестве лекарственного средства
TW200612920A (en) Novel imidazolidine derivatives
AR019790A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen. uso para preparar un medicamento
JP2016518385A5 (fr)
EP2202222A3 (fr) Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments
DE602005001552D1 (de) Fungizide zusammensetzung umfassend ein pyridylethylbenzamidderivat und eine verbindung, die zur hemmung der mitose und zellteilung fähig ist
RU2008112884A (ru) Агент для снижения инсулинорезистентности
TN2012000229A1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
TW200600085A (en) External preparation
MA41790B1 (fr) Dérivé de morphinane
MA31620B1 (fr) Perfectionnements de ou concernant des composes organiques
MX2020008982A (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.
MA27917A1 (fr) Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
RU2007147636A (ru) Средство для улучшения состояния при резистентности к инсулину
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.
FR3020809B1 (fr) Derives de 4-vinyl-2cyclopentene-1-one leur preparation et leur utilisation en tant qu'agent antibiotique
RU2007122400A (ru) Лекарственное средство и пищевой продукт или напиток для улучшения функций поджелудочной железы

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180803

PLFP Fee payment

Year of fee payment: 3

TP Transmission of property

Owner name: LABORATOIRES CERES, FR

Effective date: 20190809

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8